Can lab tests unlock hidden cancer drug options?

NCT ID NCT07343024

Recruiting now Knowledge-focused Sponsor: Cancer Commons Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see how accurate these tests are, potentially giving patients more treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify effective off-guideline cancer drugs for patients who have run out of standard options.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to new treatments directly, and results depend on real-world data from a small group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

Cancer Commons
RECRUITING

Palo Alto, California, 94306, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.